SEC Form 4 · accession 0001144204-17-018872
Protea Biosciences Group, Inc. · PRGB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Segal
Director
Period of report
Mar 24, 2017
Accepted (ET)
Apr 4, 2017 · 4:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001335103
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 24, 2017 | J | 1,000,000 | $0.00 | A | 3,633,844 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Class A Warrant (right to buy)F1,F2,F3 | $0.09 | Mar 24, 2017 | J | 1,000,000 | A | Mar 24, 2017 | Sep 24, 2018 | Common Stock | 1,000,000 | 2,916,972 | D |
| Class B Warrant (right to buy)F1,F2,F3 | $0.1125 | Mar 24, 2017 | J | 1,000,000 | A | Mar 24, 2017 | Mar 24, 2022 | Common Stock | 1,000,000 | 2,916,972 | D |
Explanation of responses
- F1Mr. Segal held $75,000 of outstanding principal indebtedness and accrued unpaid interest of the Issuer ("Unsecured Debt"). On March 24, 2017, Mr. Segal exchanged $75,000 of Unsecured Debt of the Issuer, for units of the Issuer's equity securities, consisting of (a) an aggregate of 1,000,000 shares of common stock, $0.0001 par value per share, of the Issuer ("Common Stock") valued at $0.075 per share, (b) 18 month Class A warrants to purchase 1,000,000 shares of Common Stock at an exercise price of $0.09 per share, and (c) five year Class B warrants to purchase another 1,000,000 shares at an exercise price of $0.1125 per share.
- F2The shares of Common Stock reported in Column 5 and 7 are the number of shares of Common Stock issuable upon exercise of the Class A Warrant and/or Class B Warrant (collectively, "Warrants").
- F3Includes 2,500,305 shares of Common Stock to be acquired upon the exercise of warrants and 416,667 shares of common stock to be acquired upon the exercise of stock options.